BOTHELL, WA and VANCOUVER, BC, April 25, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's
first quarter 2013 financial results will be released on Thursday, May
2, 2013, and that the Company will host a conference call and live
webcast at 4:30 p.m. ET that afternoon. Management will provide an
overview of clinical development activities and discuss the company's
To access the webcast, log on to the Investor Relations page of the
OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing
(877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A
webcast replay will be available approximately two hours after the call
and will be archived on www.oncogenex.com for 90 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NYSE: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and
in patients with advanced, unresectable non-small cell lung cancer.
OGX-427 is in Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com.
SOURCE OncoGenex Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.